http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 26 Oct 2026 15:48:45 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Aardvark+Therapeutics+Inc+%28AARD%29+PT+Lowered+to+%2410+at+Jones+Trading/27233795.html <p>Jones Trading analyst Catherine Novack lowered the price target on Aardvark Therapeutics Inc (NASDAQ: AARD) to $10.00 (from $19.00) while maintaining a Buy rating.</p> http://www.streetinsider.com/Analyst+PT+Change/Aardvark+Therapeutics+Inc+%28AARD%29+PT+Lowered+to+%2410+at+Jones+Trading/27233795.html Mon, 26 Oct 2026 15:48:45 -0400 AARD http://www.streetinsider.com/Downgrades/Oppenheimer+Downgrades+Aardvark+Therapeutics+Inc+%28AARD%29+to+Perform+%27We+Await+Visibility%27/27233156.html (Updated - October 26, 2026 1:45 PM EDT) <p>Oppenheimer analyst Leland Gershell downgraded Aardvark Therapeutics Inc (NASDAQ: AARD) from Outperform to Perform.</p><p>The analyst comments "AARD announced the lift of ARD-101's clinical hold and reported exploratory data from the prematurely-terminated Phase 3 HERO study/OLE in PWS. The results shown are compatible with a potential therapeutic effect on hyperphagia but remain hypothesis-generating. Cardiac safety data support resumption of clinical development at doses lower than the Phase 3 target dose (800mg twice-daily), for which efficacy is supported by prior open-label studies. AARD plans to seek FDA feedback on a revised Phase 3 study design http://www.streetinsider.com/Downgrades/Oppenheimer+Downgrades+Aardvark+Therapeutics+Inc+%28AARD%29+to+Perform+%27We+Await+Visibility%27/27233156.html Mon, 26 Oct 2026 13:45:36 -0400 AARD http://www.streetinsider.com/Analyst+Comments/Oppenheimer+Downgrades+Aardvark+Therapeutics+Inc+%28AARD%29+to+Perform+%27We+Await+Visibility%27/27233156.html (Updated - October 26, 2026 1:45 PM EDT) <p>Oppenheimer analyst Leland Gershell downgraded Aardvark Therapeutics Inc (NASDAQ: AARD) from Outperform to Perform.</p><p>The analyst comments "AARD announced the lift of ARD-101's clinical hold and reported exploratory data from the prematurely-terminated Phase 3 HERO study/OLE in PWS. The results shown are compatible with a potential therapeutic effect on hyperphagia but remain hypothesis-generating. Cardiac safety data support resumption of clinical development at doses lower than the Phase 3 target dose (800mg twice-daily), for which efficacy is supported by prior open-label studies. AARD plans to seek FDA feedback on a revised Phase 3 study design http://www.streetinsider.com/Analyst+Comments/Oppenheimer+Downgrades+Aardvark+Therapeutics+Inc+%28AARD%29+to+Perform+%27We+Await+Visibility%27/27233156.html Mon, 26 Oct 2026 13:45:36 -0400 AARD http://www.streetinsider.com/Press+Releases/Important+Notice+Long-Term+Shareholders+of+Aardvark+Therapeutics%2C+Inc.+%28NASDAQ%3A+AARD%29%3B+Erasca%2C+Inc.+%28NASDAQ%3A+ERAS%29%3B+Power+Solutions+International%2C+Inc.+%28NASDAQ%3A+PSIX%29%3B+and+The+Simply+Good+Foods+Compan/27231400.html <p align="justify">PHILADELPHIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- </p> <p align="justify"><strong><u>Aardvark Therapeutics, Inc. (NASDAQ: AARD)</u></strong><strong>:</strong></p> <p align="justify">Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ: AARD) shareholders who purchased shares on or shortly after the Company’s February 13, 2025, initial public offering (IPO) and have continued to hold their shares.</p> <p align="justify"><strong>What is This Investigation About?</strong> The investigation follows the filing of a securities class action against Aardvark and certain of its officers and directors alleging violations of the federal securities laws in connection with statements concerning the safety and prospects http://www.streetinsider.com/Press+Releases/Important+Notice+Long-Term+Shareholders+of+Aardvark+Therapeutics%2C+Inc.+%28NASDAQ%3A+AARD%29%3B+Erasca%2C+Inc.+%28NASDAQ%3A+ERAS%29%3B+Power+Solutions+International%2C+Inc.+%28NASDAQ%3A+PSIX%29%3B+and+The+Simply+Good+Foods+Compan/27231400.html Mon, 26 Oct 2026 08:51:57 -0400 AARD ERAS PSIX SMPL http://www.streetinsider.com/Globe+Newswire/Important+Notice+Long-Term+Shareholders+of+Aardvark+Therapeutics%2C+Inc.+%28NASDAQ%3A+AARD%29%3B+Erasca%2C+Inc.+%28NASDAQ%3A+ERAS%29%3B+Power+Solutions+International%2C+Inc.+%28NASDAQ%3A+PSIX%29%3B+and+The+Simply+Good+Foods+Compan/27231400.html <p align="justify">PHILADELPHIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- </p> <p align="justify"><strong><u>Aardvark Therapeutics, Inc. (NASDAQ: AARD)</u></strong><strong>:</strong></p> <p align="justify">Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ: AARD) shareholders who purchased shares on or shortly after the Company’s February 13, 2025, initial public offering (IPO) and have continued to hold their shares.</p> <p align="justify"><strong>What is This Investigation About?</strong> The investigation follows the filing of a securities class action against Aardvark and certain of its officers and directors alleging violations of the federal securities laws in connection with statements concerning the safety and prospects http://www.streetinsider.com/Globe+Newswire/Important+Notice+Long-Term+Shareholders+of+Aardvark+Therapeutics%2C+Inc.+%28NASDAQ%3A+AARD%29%3B+Erasca%2C+Inc.+%28NASDAQ%3A+ERAS%29%3B+Power+Solutions+International%2C+Inc.+%28NASDAQ%3A+PSIX%29%3B+and+The+Simply+Good+Foods+Compan/27231400.html Mon, 26 Oct 2026 08:51:57 -0400 AARD ERAS PSIX SMPL http://www.streetinsider.com/Press+Releases/Important+Notice+Long-Term+Shareholders+of+Aardvark+Therapeutics%2C+Inc.+%28NASDAQ%3A+AARD%29%3B+Erasca%2C+Inc.+%28NASDAQ%3A+ERAS%29%3B+Power+Solutions+International%2C+Inc.+%28NASDAQ%3A+PSIX%29%3B+and+The+Simply+Good+Foods+Compan/27231400.html <p align="justify">PHILADELPHIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- </p> <p align="justify"><strong><u>Aardvark Therapeutics, Inc. (NASDAQ: AARD)</u></strong><strong>:</strong></p> <p align="justify">Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ: AARD) shareholders who purchased shares on or shortly after the Company’s February 13, 2025, initial public offering (IPO) and have continued to hold their shares.</p> <p align="justify"><strong>What is This Investigation About?</strong> The investigation follows the filing of a securities class action against Aardvark and certain of its officers and directors alleging violations of the federal securities laws in connection with statements concerning the safety and prospects http://www.streetinsider.com/Press+Releases/Important+Notice+Long-Term+Shareholders+of+Aardvark+Therapeutics%2C+Inc.+%28NASDAQ%3A+AARD%29%3B+Erasca%2C+Inc.+%28NASDAQ%3A+ERAS%29%3B+Power+Solutions+International%2C+Inc.+%28NASDAQ%3A+PSIX%29%3B+and+The+Simply+Good+Foods+Compan/27231400.html Mon, 26 Oct 2026 08:51:57 -0400 AARD ERAS PSIX SMPL http://www.streetinsider.com/Globe+Newswire/Important+Notice+Long-Term+Shareholders+of+Aardvark+Therapeutics%2C+Inc.+%28NASDAQ%3A+AARD%29%3B+Erasca%2C+Inc.+%28NASDAQ%3A+ERAS%29%3B+Power+Solutions+International%2C+Inc.+%28NASDAQ%3A+PSIX%29%3B+and+The+Simply+Good+Foods+Compan/27231400.html <p align="justify">PHILADELPHIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- </p> <p align="justify"><strong><u>Aardvark Therapeutics, Inc. (NASDAQ: AARD)</u></strong><strong>:</strong></p> <p align="justify">Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ: AARD) shareholders who purchased shares on or shortly after the Company’s February 13, 2025, initial public offering (IPO) and have continued to hold their shares.</p> <p align="justify"><strong>What is This Investigation About?</strong> The investigation follows the filing of a securities class action against Aardvark and certain of its officers and directors alleging violations of the federal securities laws in connection with statements concerning the safety and prospects http://www.streetinsider.com/Globe+Newswire/Important+Notice+Long-Term+Shareholders+of+Aardvark+Therapeutics%2C+Inc.+%28NASDAQ%3A+AARD%29%3B+Erasca%2C+Inc.+%28NASDAQ%3A+ERAS%29%3B+Power+Solutions+International%2C+Inc.+%28NASDAQ%3A+PSIX%29%3B+and+The+Simply+Good+Foods+Compan/27231400.html Mon, 26 Oct 2026 08:51:57 -0400 AARD ERAS PSIX SMPL http://www.streetinsider.com/Press+Releases/Important+Notice+Long-Term+Shareholders+of+Aardvark+Therapeutics%2C+Inc.+%28NASDAQ%3A+AARD%29%3B+Erasca%2C+Inc.+%28NASDAQ%3A+ERAS%29%3B+Power+Solutions+International%2C+Inc.+%28NASDAQ%3A+PSIX%29%3B+and+The+Simply+Good+Foods+Compan/27231400.html <p align="justify">PHILADELPHIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- </p> <p align="justify"><strong><u>Aardvark Therapeutics, Inc. (NASDAQ: AARD)</u></strong><strong>:</strong></p> <p align="justify">Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ: AARD) shareholders who purchased shares on or shortly after the Company’s February 13, 2025, initial public offering (IPO) and have continued to hold their shares.</p> <p align="justify"><strong>What is This Investigation About?</strong> The investigation follows the filing of a securities class action against Aardvark and certain of its officers and directors alleging violations of the federal securities laws in connection with statements concerning the safety and prospects http://www.streetinsider.com/Press+Releases/Important+Notice+Long-Term+Shareholders+of+Aardvark+Therapeutics%2C+Inc.+%28NASDAQ%3A+AARD%29%3B+Erasca%2C+Inc.+%28NASDAQ%3A+ERAS%29%3B+Power+Solutions+International%2C+Inc.+%28NASDAQ%3A+PSIX%29%3B+and+The+Simply+Good+Foods+Compan/27231400.html Mon, 26 Oct 2026 08:51:57 -0400 AARD ERAS PSIX SMPL http://www.streetinsider.com/Globe+Newswire/Important+Notice+Long-Term+Shareholders+of+Aardvark+Therapeutics%2C+Inc.+%28NASDAQ%3A+AARD%29%3B+Erasca%2C+Inc.+%28NASDAQ%3A+ERAS%29%3B+Power+Solutions+International%2C+Inc.+%28NASDAQ%3A+PSIX%29%3B+and+The+Simply+Good+Foods+Compan/27231400.html <p align="justify">PHILADELPHIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- </p> <p align="justify"><strong><u>Aardvark Therapeutics, Inc. (NASDAQ: AARD)</u></strong><strong>:</strong></p> <p align="justify">Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ: AARD) shareholders who purchased shares on or shortly after the Company’s February 13, 2025, initial public offering (IPO) and have continued to hold their shares.</p> <p align="justify"><strong>What is This Investigation About?</strong> The investigation follows the filing of a securities class action against Aardvark and certain of its officers and directors alleging violations of the federal securities laws in connection with statements concerning the safety and prospects http://www.streetinsider.com/Globe+Newswire/Important+Notice+Long-Term+Shareholders+of+Aardvark+Therapeutics%2C+Inc.+%28NASDAQ%3A+AARD%29%3B+Erasca%2C+Inc.+%28NASDAQ%3A+ERAS%29%3B+Power+Solutions+International%2C+Inc.+%28NASDAQ%3A+PSIX%29%3B+and+The+Simply+Good+Foods+Compan/27231400.html Mon, 26 Oct 2026 08:51:57 -0400 AARD ERAS PSIX SMPL http://www.streetinsider.com/Press+Releases/Important+Notice+Long-Term+Shareholders+of+Aardvark+Therapeutics%2C+Inc.+%28NASDAQ%3A+AARD%29%3B+Erasca%2C+Inc.+%28NASDAQ%3A+ERAS%29%3B+Power+Solutions+International%2C+Inc.+%28NASDAQ%3A+PSIX%29%3B+and+The+Simply+Good+Foods+Compan/27231400.html <p align="justify">PHILADELPHIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- </p> <p align="justify"><strong><u>Aardvark Therapeutics, Inc. (NASDAQ: AARD)</u></strong><strong>:</strong></p> <p align="justify">Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ: AARD) shareholders who purchased shares on or shortly after the Company’s February 13, 2025, initial public offering (IPO) and have continued to hold their shares.</p> <p align="justify"><strong>What is This Investigation About?</strong> The investigation follows the filing of a securities class action against Aardvark and certain of its officers and directors alleging violations of the federal securities laws in connection with statements concerning the safety and prospects http://www.streetinsider.com/Press+Releases/Important+Notice+Long-Term+Shareholders+of+Aardvark+Therapeutics%2C+Inc.+%28NASDAQ%3A+AARD%29%3B+Erasca%2C+Inc.+%28NASDAQ%3A+ERAS%29%3B+Power+Solutions+International%2C+Inc.+%28NASDAQ%3A+PSIX%29%3B+and+The+Simply+Good+Foods+Compan/27231400.html Mon, 26 Oct 2026 08:51:57 -0400 AARD ERAS PSIX SMPL http://www.streetinsider.com/Globe+Newswire/Important+Notice+Long-Term+Shareholders+of+Aardvark+Therapeutics%2C+Inc.+%28NASDAQ%3A+AARD%29%3B+Erasca%2C+Inc.+%28NASDAQ%3A+ERAS%29%3B+Power+Solutions+International%2C+Inc.+%28NASDAQ%3A+PSIX%29%3B+and+The+Simply+Good+Foods+Compan/27231400.html <p align="justify">PHILADELPHIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- </p> <p align="justify"><strong><u>Aardvark Therapeutics, Inc. (NASDAQ: AARD)</u></strong><strong>:</strong></p> <p align="justify">Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ: AARD) shareholders who purchased shares on or shortly after the Company’s February 13, 2025, initial public offering (IPO) and have continued to hold their shares.</p> <p align="justify"><strong>What is This Investigation About?</strong> The investigation follows the filing of a securities class action against Aardvark and certain of its officers and directors alleging violations of the federal securities laws in connection with statements concerning the safety and prospects http://www.streetinsider.com/Globe+Newswire/Important+Notice+Long-Term+Shareholders+of+Aardvark+Therapeutics%2C+Inc.+%28NASDAQ%3A+AARD%29%3B+Erasca%2C+Inc.+%28NASDAQ%3A+ERAS%29%3B+Power+Solutions+International%2C+Inc.+%28NASDAQ%3A+PSIX%29%3B+and+The+Simply+Good+Foods+Compan/27231400.html Mon, 26 Oct 2026 08:51:57 -0400 AARD ERAS PSIX SMPL http://www.streetinsider.com/Analyst+PT+Change/Aardvark+Therapeutics+Inc+%28AARD%29+PT+Lowered+to+%242+at+H.C.+Wainwright/27230379.html (Updated - October 26, 2026 7:06 AM EDT) <p>H.C. Wainwright analyst Raghuram Selvaraju lowered the price target on Aardvark Therapeutics Inc (NASDAQ: AARD) to $2.00 (from $4.00) while maintaining a Neutral rating.</p><p>The analyst commented: "ARD-101 clinical hold lifted with initial drug impact seen, yet questions remain—lowering price target. Late last week, Aardvark Therapeutics announced that the FDA had lifted the clinical hold on the company’s Investigational New Drug (IND) application for ARD-101 for the treatment of hyperphagia in Prader-Willi Syndrome (PWS). As a reminder, on February 27, 2026, Aardvark voluntarily paused dosing in the Phase 3 Hunger Elimination or Reduction Objective http://www.streetinsider.com/Analyst+PT+Change/Aardvark+Therapeutics+Inc+%28AARD%29+PT+Lowered+to+%242+at+H.C.+Wainwright/27230379.html Mon, 26 Oct 2026 07:06:19 -0400 AARD http://www.streetinsider.com/Analyst+Comments/Aardvark+Therapeutics+Inc+%28AARD%29+PT+Lowered+to+%242+at+H.C.+Wainwright/27230379.html (Updated - October 26, 2026 7:06 AM EDT) <p>H.C. Wainwright analyst Raghuram Selvaraju lowered the price target on Aardvark Therapeutics Inc (NASDAQ: AARD) to $2.00 (from $4.00) while maintaining a Neutral rating.</p><p>The analyst commented: "ARD-101 clinical hold lifted with initial drug impact seen, yet questions remain—lowering price target. Late last week, Aardvark Therapeutics announced that the FDA had lifted the clinical hold on the company’s Investigational New Drug (IND) application for ARD-101 for the treatment of hyperphagia in Prader-Willi Syndrome (PWS). As a reminder, on February 27, 2026, Aardvark voluntarily paused dosing in the Phase 3 Hunger Elimination or Reduction Objective http://www.streetinsider.com/Analyst+Comments/Aardvark+Therapeutics+Inc+%28AARD%29+PT+Lowered+to+%242+at+H.C.+Wainwright/27230379.html Mon, 26 Oct 2026 07:06:19 -0400 AARD http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aardvark+Therapeutics%2C++++For%3A+Oct+23/27225428.html si-local-file:///var/storage/secattach/20261023/27225428.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aardvark+Therapeutics%2C++++For%3A+Oct+23/27225428.html Fri, 23 Oct 2026 08:39:00 -0400 AARD http://www.streetinsider.com/Corporate+News/Aardvark+Therapeutics+%28AARD%29+Reports+Exploratory+Data+from+the+Terminated+HERO+and+Open-Label+Extension+Trials/27224860.html <p>Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of Prader-Willi syndrome (PWS) and metabolic diseases, today reported exploratory efficacy data from its previously terminated Phase 3 Hunger Elimination or Reduction Objective (HERO) trial and open-label extension (OLE) trial. As previously announced, Aardvark unblinded the data accumulated across both the HERO trial and OLE trial to assess the totality of available efficacy and safety data to inform the path forward for ARD-101.</p><p>“Though the HERO trial was stopped early and the current partial data are not http://www.streetinsider.com/Corporate+News/Aardvark+Therapeutics+%28AARD%29+Reports+Exploratory+Data+from+the+Terminated+HERO+and+Open-Label+Extension+Trials/27224860.html Fri, 23 Oct 2026 07:01:14 -0400 AARD http://www.streetinsider.com/FDA/Aardvark+Therapeutics+%28AARD%29+Reports+Exploratory+Data+from+the+Terminated+HERO+and+Open-Label+Extension+Trials/27224860.html <p>Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of Prader-Willi syndrome (PWS) and metabolic diseases, today reported exploratory efficacy data from its previously terminated Phase 3 Hunger Elimination or Reduction Objective (HERO) trial and open-label extension (OLE) trial. As previously announced, Aardvark unblinded the data accumulated across both the HERO trial and OLE trial to assess the totality of available efficacy and safety data to inform the path forward for ARD-101.</p><p>“Though the HERO trial was stopped early and the current partial data are not http://www.streetinsider.com/FDA/Aardvark+Therapeutics+%28AARD%29+Reports+Exploratory+Data+from+the+Terminated+HERO+and+Open-Label+Extension+Trials/27224860.html Fri, 23 Oct 2026 07:01:14 -0400 AARD http://www.streetinsider.com/Press+Releases/Aardvark+Therapeutics+Reports+Exploratory+Data+from+the+Terminated+HERO+and+Open-Label+Extension+Trials/27224819.html <ul type="disc"><li style="list-style-position:inside; margin-bottom:8pt; text-align:center;"><strong><em>HERO trial terminated early (67 of 90 planned participants randomized); all efficacy data are considered exploratory</em></strong></li><li style="list-style-position:inside; margin-bottom:8pt; text-align:center;"><strong><em>HQ-CT scores fell by Week 2 of dose escalation on ARD-101 and returned to near baseline within two weeks of stopping treatment, with less rebound on placebo</em></strong></li><li style="list-style-position:inside; margin-bottom:8pt; text-align:center;"><strong><em>OLE participants switching from placebo to ARD-101 saw a further reduction in HQ-CT scores by Day 28</em></strong></li><li style="list-style-position:inside; margin-bottom:8pt; text-align:center;"><strong><em>ARD-101 was well tolerated; most adverse events mild to moderate</em></strong></li><li style="list-style-position:inside; margin-bottom:8pt; text-align:center;"><strong><em>FDA lifted full clinical hold on ARD-101; Company plans to request FDA meeting to align on new Phase http://www.streetinsider.com/Press+Releases/Aardvark+Therapeutics+Reports+Exploratory+Data+from+the+Terminated+HERO+and+Open-Label+Extension+Trials/27224819.html Fri, 23 Oct 2026 07:00:00 -0400 AARD http://www.streetinsider.com/Globe+Newswire/Aardvark+Therapeutics+Reports+Exploratory+Data+from+the+Terminated+HERO+and+Open-Label+Extension+Trials/27224819.html <ul type="disc"><li style="list-style-position:inside; margin-bottom:8pt; text-align:center;"><strong><em>HERO trial terminated early (67 of 90 planned participants randomized); all efficacy data are considered exploratory</em></strong></li><li style="list-style-position:inside; margin-bottom:8pt; text-align:center;"><strong><em>HQ-CT scores fell by Week 2 of dose escalation on ARD-101 and returned to near baseline within two weeks of stopping treatment, with less rebound on placebo</em></strong></li><li style="list-style-position:inside; margin-bottom:8pt; text-align:center;"><strong><em>OLE participants switching from placebo to ARD-101 saw a further reduction in HQ-CT scores by Day 28</em></strong></li><li style="list-style-position:inside; margin-bottom:8pt; text-align:center;"><strong><em>ARD-101 was well tolerated; most adverse events mild to moderate</em></strong></li><li style="list-style-position:inside; margin-bottom:8pt; text-align:center;"><strong><em>FDA lifted full clinical hold on ARD-101; Company plans to request FDA meeting to align on new Phase http://www.streetinsider.com/Globe+Newswire/Aardvark+Therapeutics+Reports+Exploratory+Data+from+the+Terminated+HERO+and+Open-Label+Extension+Trials/27224819.html Fri, 23 Oct 2026 07:00:00 -0400 AARD http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aardvark+Therapeutics%2C++++For%3A+Oct+22/27222913.html si-local-file:///var/storage/secattach/20261022/27222913.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aardvark+Therapeutics%2C++++For%3A+Oct+22/27222913.html Thu, 22 Oct 2026 16:17:00 -0400 AARD http://www.streetinsider.com/FDA/FDA+lifts+clinical+hold+on+Aardvark%27s+ARD-101+for+Prader-Willi/27222594.html <p>Aardvark Therapeutics, Inc. (Nasdaq: AARD) announced that the U.S. Food and Drug Administration has lifted the clinical hold on the company's Investigational New Drug application for ARD-101, an oral small-molecule treatment for hyperphagia associated with Prader-Willi Syndrome.</p> <p>The FDA placed the clinical hold in May 2026, following a voluntary pause in dosing that Aardvark initiated on February 27, 2026, after reversible electrocardiogram changes were observed in healthy volunteers during a separate study. In response, the company conducted an ECG study in additional healthy volunteers and an in vitro cardiac sodium channel study. No cardiac events were observed at ARD-101 doses of http://www.streetinsider.com/FDA/FDA+lifts+clinical+hold+on+Aardvark%27s+ARD-101+for+Prader-Willi/27222594.html Thu, 22 Oct 2026 16:05:30 -0400 AARD http://www.streetinsider.com/Press+Releases/Aardvark+Therapeutics+Announces+FDA+Has+Lifted+the+Clinical+Hold+on+ARD-101+for+the+Treatment+of+Prader-Willi+Syndrome+and+Will+Host+Webcast+to+Review+the+Available+Exploratory+Phase+3+HEROOLE+Data/27222531.html <p align="center"><strong><em>Clinical development of ARD-101 for hyperphagia in Prader-Willi Syndrome (PWS) may resume</em></strong></p> <p align="center"><strong><em>Aardvark will host a webcast to review available dataset from the terminated Phase 3 HERO trial and OLE trial on Friday, October 23, 2026, at 8:00 a.m. EST</em></strong></p> <p>SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of Prader-Willi Syndrome (PWS) and metabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold http://www.streetinsider.com/Press+Releases/Aardvark+Therapeutics+Announces+FDA+Has+Lifted+the+Clinical+Hold+on+ARD-101+for+the+Treatment+of+Prader-Willi+Syndrome+and+Will+Host+Webcast+to+Review+the+Available+Exploratory+Phase+3+HEROOLE+Data/27222531.html Thu, 22 Oct 2026 16:05:00 -0400 AARD http://www.streetinsider.com/Globe+Newswire/Aardvark+Therapeutics+Announces+FDA+Has+Lifted+the+Clinical+Hold+on+ARD-101+for+the+Treatment+of+Prader-Willi+Syndrome+and+Will+Host+Webcast+to+Review+the+Available+Exploratory+Phase+3+HEROOLE+Data/27222531.html <p align="center"><strong><em>Clinical development of ARD-101 for hyperphagia in Prader-Willi Syndrome (PWS) may resume</em></strong></p> <p align="center"><strong><em>Aardvark will host a webcast to review available dataset from the terminated Phase 3 HERO trial and OLE trial on Friday, October 23, 2026, at 8:00 a.m. EST</em></strong></p> <p>SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of Prader-Willi Syndrome (PWS) and metabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold http://www.streetinsider.com/Globe+Newswire/Aardvark+Therapeutics+Announces+FDA+Has+Lifted+the+Clinical+Hold+on+ARD-101+for+the+Treatment+of+Prader-Willi+Syndrome+and+Will+Host+Webcast+to+Review+the+Available+Exploratory+Phase+3+HEROOLE+Data/27222531.html Thu, 22 Oct 2026 16:05:00 -0400 AARD http://www.streetinsider.com/Press+Releases/Attention+Long-Term+Shareholders+of+Aardvark+Therapeutics%2C+Inc.+%28NASDAQ%3A+AARD%29%3B+Erasca%2C+Inc.+%28NASDAQ%3A+ERAS%29%3B+GPGI%2C+Inc.%2C+fka+CompoSecure%2C+Inc.+%28NYSE%3A+GPGI%29%3B+and+New+Era+Energy+%26+Digital%2C+Inc.+%28NASDA/27213598.html <p align="justify">PHILADELPHIA , Oct. 21, 2026 (GLOBE NEWSWIRE) -- </p> <p align="justify"><strong><u>Aardvark Therapeutics, Inc. (NASDAQ: AARD)</u></strong><strong>:</strong></p> <p align="justify">Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ: AARD) shareholders who purchased shares on or shortly after the Company’s February 13, 2025, initial public offering (IPO) and have continued to hold their shares.</p> <p align="justify"><strong>What is This Investigation About?</strong> The investigation follows the filing of a securities class action against Aardvark and certain of its officers and directors alleging violations of the federal securities laws in connection with statements concerning the safety and http://www.streetinsider.com/Press+Releases/Attention+Long-Term+Shareholders+of+Aardvark+Therapeutics%2C+Inc.+%28NASDAQ%3A+AARD%29%3B+Erasca%2C+Inc.+%28NASDAQ%3A+ERAS%29%3B+GPGI%2C+Inc.%2C+fka+CompoSecure%2C+Inc.+%28NYSE%3A+GPGI%29%3B+and+New+Era+Energy+%26+Digital%2C+Inc.+%28NASDA/27213598.html Wed, 21 Oct 2026 08:24:48 -0400 AARD ERAS GPGI NEHC NUAI http://www.streetinsider.com/Globe+Newswire/Attention+Long-Term+Shareholders+of+Aardvark+Therapeutics%2C+Inc.+%28NASDAQ%3A+AARD%29%3B+Erasca%2C+Inc.+%28NASDAQ%3A+ERAS%29%3B+GPGI%2C+Inc.%2C+fka+CompoSecure%2C+Inc.+%28NYSE%3A+GPGI%29%3B+and+New+Era+Energy+%26+Digital%2C+Inc.+%28NASDA/27213598.html <p align="justify">PHILADELPHIA , Oct. 21, 2026 (GLOBE NEWSWIRE) -- </p> <p align="justify"><strong><u>Aardvark Therapeutics, Inc. (NASDAQ: AARD)</u></strong><strong>:</strong></p> <p align="justify">Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ: AARD) shareholders who purchased shares on or shortly after the Company’s February 13, 2025, initial public offering (IPO) and have continued to hold their shares.</p> <p align="justify"><strong>What is This Investigation About?</strong> The investigation follows the filing of a securities class action against Aardvark and certain of its officers and directors alleging violations of the federal securities laws in connection with statements concerning the safety and http://www.streetinsider.com/Globe+Newswire/Attention+Long-Term+Shareholders+of+Aardvark+Therapeutics%2C+Inc.+%28NASDAQ%3A+AARD%29%3B+Erasca%2C+Inc.+%28NASDAQ%3A+ERAS%29%3B+GPGI%2C+Inc.%2C+fka+CompoSecure%2C+Inc.+%28NYSE%3A+GPGI%29%3B+and+New+Era+Energy+%26+Digital%2C+Inc.+%28NASDA/27213598.html Wed, 21 Oct 2026 08:24:48 -0400 AARD ERAS GPGI NEHC NUAI http://www.streetinsider.com/Press+Releases/Attention+Long-Term+Shareholders+of+Aardvark+Therapeutics%2C+Inc.+%28NASDAQ%3A+AARD%29%3B+Erasca%2C+Inc.+%28NASDAQ%3A+ERAS%29%3B+GPGI%2C+Inc.%2C+fka+CompoSecure%2C+Inc.+%28NYSE%3A+GPGI%29%3B+and+New+Era+Energy+%26+Digital%2C+Inc.+%28NASDA/27213598.html <p align="justify">PHILADELPHIA , Oct. 21, 2026 (GLOBE NEWSWIRE) -- </p> <p align="justify"><strong><u>Aardvark Therapeutics, Inc. (NASDAQ: AARD)</u></strong><strong>:</strong></p> <p align="justify">Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ: AARD) shareholders who purchased shares on or shortly after the Company’s February 13, 2025, initial public offering (IPO) and have continued to hold their shares.</p> <p align="justify"><strong>What is This Investigation About?</strong> The investigation follows the filing of a securities class action against Aardvark and certain of its officers and directors alleging violations of the federal securities laws in connection with statements concerning the safety and http://www.streetinsider.com/Press+Releases/Attention+Long-Term+Shareholders+of+Aardvark+Therapeutics%2C+Inc.+%28NASDAQ%3A+AARD%29%3B+Erasca%2C+Inc.+%28NASDAQ%3A+ERAS%29%3B+GPGI%2C+Inc.%2C+fka+CompoSecure%2C+Inc.+%28NYSE%3A+GPGI%29%3B+and+New+Era+Energy+%26+Digital%2C+Inc.+%28NASDA/27213598.html Wed, 21 Oct 2026 08:24:48 -0400 AARD ERAS GPGI NEHC NUAI